caa a22 4500 469064021 CHVBK 20180323132902.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF02914374 doi (NATIONALLICENCE)springer-10.1007/BF02914374 Ann Parke University of Connecticut Health Center, Department of Medicine, Division of Rheumatic Diseases, Farmington, CT aut The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses [Elektronische Daten] [Parke Ann] Intravenous immune γ-globulin appears to have a role in the management of some autoimmune-mediated diseases. The exact mechanisms whereby IVIG is beneficial to patients with these diseases are not understood. The antiphospholipid-antibody syndrome is a recently recognized syndrome in which antibodies to negatively charged phospholipids are associated with a thrombotic diathesis, fetal wastage, and thrombocytopenia. The association between these antibodies and the clinical complaints is unknown. Recent evidence has suggested that a cofactor, a serum protein or glycoprotein (of approx 50 kDa) is essential for so-called antiphospholipid antibodies to bind to phospholipids (46,47). It may be that variations in this cofactor and its binding are some of the factors that determine whether high levels of antiphospholipid antibodies result in pathological consequences. Patients with antiphospholipid antibodies who have experienced previous fetal losses will continue to experience fetal wastage without some form, of therapeutic intervention (33,34). The optimum therapy for these patients is yet to be determined, but recent isolated anecdotal reports suggest that IVIG may be of some benefit. IVIG appears to be less toxic to the mother than prednisone. The true benefit of IVIG, however, can be determined only by randomized, well controlled trials. The Humana Press Inc, 1992 Clinical Reviews in Allergy Humana Press 10/1-2(1992-03-01), 105-118 0731-8235 10:1-2<105 1992 10 12016 https://doi.org/10.1007/BF02914374 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02914374 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Ann Parke University of Connecticut Health Center, Department of Medicine, Division of Rheumatic Diseases, Farmington, CT aut NATIONALLICENCE 773 0- Clinical Reviews in Allergy Humana Press 10/1-2(1992-03-01), 105-118 0731-8235 10:1-2<105 1992 10 12016 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer